EVE Health Breaks Ground with First Dyspro™ Prescriptions and Libbo™ Launch Prep

Commercial Transition Achieved

EVE Health Group (ASX, EVE) has marked a pivotal shift from product development to active patient access in its December 2025 quarterly update. The company announced that Dyspro™, its cannabinoid-based treatment targeting dysmenorrhoea and endometriosis, was prescribed to patients for the first time under Australia's Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber pathways. This milestone signals EVE’s entry into real-world clinical application, moving beyond manufacturing into commercial execution.

Simultaneously, EVE completed the initial commercial manufacturing run of Libbo™, an oral dissolving film designed for erectile dysfunction. The finished inventory has been distributed nationally, setting the stage for imminent market launch through telehealth and pharmacy channels. This dual progress across women’s and men’s health portfolios underscores EVE’s strategic focus on addressing underserved therapeutic areas with innovative delivery technologies.

Supporting Infrastructure and Education

Recognising the importance of clinician engagement and patient support in successful commercialisation, EVE has appointed its first dedicated Medical Science Liaison. This role is critical in educating prescribers and fostering clinical confidence in the new therapies. Complementing this, the company launched a national patient support program in partnership with telehealth provider hubMed. This initiative aims to enhance continuity of care by providing regular nurse-led follow-ups, ensuring safe and effective use of Dyspro™ and Libbo™.

Further bolstering patient and practitioner engagement, EVE introduced the Reclaim My Cycle platform, an online community and education resource for women managing period pain and endometriosis. The platform includes a clinician-led case study program offering eligible participants access to medical care at no cost, reflecting EVE’s commitment to building awareness and supporting appropriate patient selection.

Financial Position and Outlook

To accelerate its commercial rollout, EVE successfully raised $1.1 million in a placement to sophisticated investors in October 2025. The funds are earmarked for prescriber education, patient access initiatives, and regulatory advancement toward export-only and full Therapeutic Goods Administration registration. At quarter end, the company held $0.9 million in cash, with customer receipts steady at $0.3 million for the period.

Looking ahead, EVE plans to activate prescribing and digital marketing platforms for Libbo™, continue health practitioner education for Dyspro™, and progress regulatory registrations. The company is also exploring additional product opportunities leveraging its solubility technology to repurpose established pharmaceuticals, aiming to expand its pipeline and commercial footprint.

Strategic Implications

CEO Damian Wood emphasised the significance of this quarter’s achievements, highlighting the transition from manufacturing to patient outcomes. The coordinated approach combining product readiness, clinical engagement, and patient support positions EVE well for scaling its market presence. However, with a modest cash runway, the company’s ability to sustain momentum will depend on successful market uptake and potential future capital raises.